RU2319504C2 - Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты) - Google Patents

Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты) Download PDF

Info

Publication number
RU2319504C2
RU2319504C2 RU2002132833/13A RU2002132833A RU2319504C2 RU 2319504 C2 RU2319504 C2 RU 2319504C2 RU 2002132833/13 A RU2002132833/13 A RU 2002132833/13A RU 2002132833 A RU2002132833 A RU 2002132833A RU 2319504 C2 RU2319504 C2 RU 2319504C2
Authority
RU
Russia
Prior art keywords
vaccine
plasmid
dog
promoter
nucleic acid
Prior art date
Application number
RU2002132833/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2002132833A (ru
Inventor
Жан-Кристоф ОДОННЕ (FR)
Жан-Кристоф Одонне
Аннабелль БУШАРДОН (FR)
Аннабелль Бушардон
Мишель РИВЬЕР (FR)
Мишель Ривьер
Original Assignee
Мериаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2319504(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мериаль filed Critical Мериаль
Publication of RU2002132833A publication Critical patent/RU2002132833A/ru
Application granted granted Critical
Publication of RU2319504C2 publication Critical patent/RU2319504C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2002132833/13A 1996-07-19 1997-07-15 Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты) RU2319504C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609401 1996-07-19
FR9609401A FR2751227B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU99103298/13A Division RU99103298A (ru) 1996-07-19 1997-07-15 Формула полинуклеотидной вакцины против патологий собак, в частности, респираторных патологий и патологий пищеварения

Publications (2)

Publication Number Publication Date
RU2002132833A RU2002132833A (ru) 2005-01-20
RU2319504C2 true RU2319504C2 (ru) 2008-03-20

Family

ID=9494495

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002132833/13A RU2319504C2 (ru) 1996-07-19 1997-07-15 Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты)

Country Status (17)

Country Link
US (2) US6228846B1 (enExample)
EP (1) EP0954332B2 (enExample)
JP (1) JP2000515521A (enExample)
KR (3) KR20050087885A (enExample)
AR (1) AR034997A1 (enExample)
AU (1) AU733563B2 (enExample)
BR (1) BR9710509A (enExample)
CA (1) CA2260273C (enExample)
CZ (1) CZ300385B6 (enExample)
DE (1) DE69731309T3 (enExample)
FR (1) FR2751227B1 (enExample)
NZ (1) NZ333780A (enExample)
PL (1) PL190150B1 (enExample)
RU (1) RU2319504C2 (enExample)
TW (1) TW587942B (enExample)
WO (1) WO1998003199A1 (enExample)
ZA (1) ZA976284B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626605C2 (ru) * 2015-11-25 2017-07-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации
RU2707544C1 (ru) * 2018-12-28 2019-11-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая конструкция на основе оптимизированного гена консенсусного гликопротеина вируса бешенства для профилактики бешенства
RU2712743C2 (ru) * 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7294338B2 (en) * 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
EP0863151A1 (en) * 1997-02-12 1998-09-09 Akzo Nobel N.V. "Canine parvovirus dna vaccines"
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
CA2375320C (en) * 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
WO2002078732A1 (en) * 2001-02-15 2002-10-10 The Registrar, Indian Institute Of Science A noval vaccine formulation consisting of dna vaccine inactivated virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
CA2510189A1 (en) * 2002-12-19 2004-07-08 Thomas Gore Trivalent vaccine with maternal antibody transfer via the milk
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US8541003B2 (en) 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
WO2005112544A2 (en) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
WO2007115059A2 (en) 2006-03-29 2007-10-11 Merial Limited Vaccine against streptococci
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
EP2611460B1 (en) 2010-08-31 2016-10-05 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2012149038A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837582C (en) 2011-05-27 2021-03-02 Merial Limited Genetic vaccines against hendra virus and nipah virus
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
MX350096B (es) 2011-08-12 2017-08-25 Merial Inc Preservación asistida con vacío de productos biológicos, en particular de vacunas.
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
SI2814508T1 (sl) 2012-02-14 2017-10-30 Merial, Inc. Rotavirusna podenotska cepiva ter postopki njihove izdelave in uporaba
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2861248B1 (en) 2012-06-13 2017-11-15 Merial, Inc. Reassortant btv and ahsv vaccines
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2016073410A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
HUE065661T2 (hu) 2015-09-29 2024-06-28 Boehringer Ingelheim Animal Health Usa Inc Kutya parvovírus (CPV) vírusszerû részecske (VLP) vakcinák és alkalmazásuk
DK3380119T3 (da) 2015-11-23 2021-11-15 Boehringer Ingelheim Animal Health Usa Inc Fmdv- og e2-fusionsproteiner og anvendelser deraf
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108704128B (zh) * 2018-05-15 2022-06-21 青岛农业大学 一种犬瘟热细小病毒二联亚单位疫苗
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN116735873B (zh) * 2023-08-09 2023-10-31 北京纳百生物科技有限公司 特异性结合犬细小病毒vp2蛋白的单克隆抗体在检测试剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU56248A1 (enExample) * 1968-06-11 1970-01-15
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
JP4117027B2 (ja) 1996-04-19 2008-07-09 コルパン メチン パルボウイルス感染のための核酸予防接種
EP0954582A1 (en) 1996-04-29 1999-11-10 Andreas Prof. Zurbriggen Polynucleotide vaccine against canine distemper
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
IT1292422B1 (it) * 1997-06-26 1999-02-08 Agip Petroli Reattore a bolle con draft tube e procedimento per la rigenerazione del catalizzatore in esso contenuto
US6063385A (en) * 1997-11-07 2000-05-16 Wisconsin Alumni Research Foundation DNA vaccine for parvovirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIANG Z.Q. et al. "Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus". Virology. 1994 Feb 15; 199(1):132-40. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712743C2 (ru) * 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
RU2626605C2 (ru) * 2015-11-25 2017-07-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации
RU2707544C1 (ru) * 2018-12-28 2019-11-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая конструкция на основе оптимизированного гена консенсусного гликопротеина вируса бешенства для профилактики бешенства

Also Published As

Publication number Publication date
DE69731309T2 (de) 2005-11-17
RU2002132833A (ru) 2005-01-20
PL190150B1 (pl) 2005-11-30
AU3699397A (en) 1998-02-10
DE69731309D1 (de) 2004-11-25
US6586412B2 (en) 2003-07-01
EP0954332B2 (fr) 2014-12-31
KR100620302B1 (ko) 2006-09-06
TW587942B (en) 2004-05-21
CZ15899A3 (cs) 1999-05-12
CA2260273A1 (en) 1998-01-29
EP0954332B1 (fr) 2004-10-20
WO1998003199A1 (fr) 1998-01-29
FR2751227A1 (fr) 1998-01-23
BR9710509A (pt) 1999-08-17
KR20060013432A (ko) 2006-02-09
KR20050087885A (ko) 2005-08-31
AU733563B2 (en) 2001-05-17
FR2751227B1 (fr) 1998-11-27
NZ333780A (en) 2000-10-27
DE69731309T3 (de) 2015-06-03
PL331246A1 (en) 1999-07-05
US6228846B1 (en) 2001-05-08
EP0954332A1 (fr) 1999-11-10
US20010009959A1 (en) 2001-07-26
KR20000067866A (ko) 2000-11-25
ZA976284B (en) 1999-01-19
JP2000515521A (ja) 2000-11-21
AR034997A1 (es) 2004-04-14
CZ300385B6 (cs) 2009-05-06
CA2260273C (en) 2010-12-21

Similar Documents

Publication Publication Date Title
RU2319504C2 (ru) Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты)
RU2312676C2 (ru) Формула кошачьей вакцины
CA2660355C (en) Polynucleotide vaccine formulation against pathologies of the horse
US6376473B1 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
RU2305559C2 (ru) Вакцина свиней против респираторных патологий и патологий репродукции свиней
CN1225685A (zh) 禽多核苷酸疫苗制剂
AU2844899A (en) Adjuvant-containing vaccines
US7294338B2 (en) Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
AU776827B2 (en) Polynucleotide vaccine formula, particularly for treating bovine respiratory disease
AU765539B2 (en) Polynucleotide vaccine formula for treating horse diseases
AU2004205140B2 (en) Feline polynucleotide vaccine formula
AU773266B2 (en) Feline polynucleotide vaccine formula
NZ506427A (en) A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter
HK1083763A (zh) 针对马科动物病变的多核苷酸疫苗配方
AU2007202367A1 (en) Avian polynucleotide vaccine formula